Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus

Arthritis Care and Research

Volumn 63, Issue 3, 2011, Pages 342-350

  Daleboudt, Gabriëlle M N ^a,b   Broadbent, Elizabeth ^b   McQueen, Fiona ^c   Kaptein, Ad A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; COGNITION; EMOTIONAL STABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PATIENT COMPLIANCE; PERCEPTION; PREDICTOR VARIABLE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SELF REPORT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; AGE; ANALYSIS OF VARIANCE; ATTITUDE TO HEALTH; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; EMOTION; HEALTH BEHAVIOR; MIDDLE AGED; NEW ZEALAND; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COGNITION; CROSS-SECTIONAL STUDIES; EMOTIONS; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEW ZEALAND; PERCEPTION; RISK ASSESSMENT; RISK FACTORS; SELF REPORT; TREATMENT OUTCOME;

EID: 84858060056     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.20411     Document Type: Article

References (42)

1. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 2002;47:630-8. (Pubitemid 35461316)
2. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus ery-thematosus. Clin Rheumatol 2008;27:883-9.
3. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009;61:240-6.
4. Mirotznik J, Ginzler E, Zagon G, Baptiste A. Using the health belief model to explain clinic appointment-keeping for the management of a chronic disease condition. J Community Health 1998;23:195-210. (Pubitemid 28240771)
5. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-53.
6. Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit: causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000;9:601-6.
7. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006;45:1144-7. (Pubitemid 44542106)
8. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, O'Malley KJ, Janssen NM, Marcus DM, et al. Determinants of treatment adherence in ethnically diverse, economically dis-advantaged patients with rheumatic disease. J Rheumatol 2005;32:913-9. (Pubitemid 40676504)
9. Kumar K, Gordon C, Toescu V, Buckley CD, Horne R, Nightingale PG, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford) 2008;47:690-7. (Pubitemid 351619214)
10. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford) 2009;48:266-71.
11. Seawell AH, Danoff-Burg S. Psychosocial research on systemic lupus erythematosus: a literature review. Lupus 2004; 13:891-9. (Pubitemid 39664946)
12. Manson JJ, Rahman A. Systemic lupus erythematosus. Orpha-net J Rare Dis 2006;1:6. URL: http://www.ojrd.com/content/1/1/6.
13. Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007;44:1468-77.
14. Horne R. Representations of medication and treatment: advances in theory and assessment. In: Petrie KJ, Weinman J, editors. Perceptions of health and illness. Chur (Switzerland): Harwood; 1997. p. 155-88.
15. Morrison V, Bennett P. An introduction to health psychology. Harlow Essex (UK): Pearson Education Limited; 2006.
16. Leventhal H, Meyer D, Nerenz D. The common sense model of illness danger. In: Rachman S, editor. Medical Psychology. Vol. 2. New York: Pergamon; 1980. p. 7-30.
17. Olazaran J, Lopez-Longo J, Cruz I, Bittini A, Carreno L. Cognitive dysfunction in systemic lupus erythematosus: prevalence and correlates. Eur Neurol 2009;62:49-55.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7. (Pubitemid 13221242)
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
20. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002;16:269-77. (Pubitemid 34118574)
21. Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, et al. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007;57:1000-6. (Pubitemid 47237326)
22. Horne R, Clatworthy J, Polmear A, Weinman J. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life? J Hum Hyper-tens 2001;15:S65-8. (Pubitemid 32904113)
23. Pincus T, Swearingen C, Callahan LF. A self-report cognitive symptoms inventory to assess patients with rheumatic diseases: results in eosinophilia-myalgia syndrome (EMS), fibromyalgia, rheumatoid arthritis (RA), and other rheumatic diseases abstract. Arthritis Rheum 1996;39 Suppl:S261.
24. Alarcon GS, Cianfrini L, Bradley LA, Sanchez ML, Brooks K, Friedman AW, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the cognitive symptoms inventory. Arthritis Rheum 2002;47:310-9. (Pubitemid 34627700)
25. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
26. Broadbent E, Petrie KJ, Main J, Weinman J. The Brief Illness Perception Questionnaire. J Psychosom Res 2006;60:631-7. (Pubitemid 43786439)
27. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972-9. (Pubitemid 47237322)
28. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheu-matol 1992;19:53-9.
29. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus: prospective validation of 3 clinical indices. J Rheumatol 1992;19:1551-8.
30. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20:657-60. (Pubitemid 23138854)
31. Statistics New Zealand. 2006 census of population and dwellings. 2006. URL: http://www.stats.govt.nz/Census/2006Cen-susHomePage.aspx.
32. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402.
33. Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, et al. Adherence to medications in systemic lupus ery-thematosus. J Clin Rheumatol 2008;14:195-201.
34. Nived O, Andersson M, Lindgren M, Malcus-Johnsson P, Nihlberg A, Nived K, et al. Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire. Lupus 2007;16:701-6. (Pubitemid 47517864)
35. Chambers S, Raine R, Rahman A, Hagley K, De CK, Isenberg D. Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus 2008;17:761-9.
36. Stilley CS, Bender CM, Dunbar-Jacob J, Sereika S, Ryan CM. The impact of cognitive function on medication management: three studies. Health Psychol 2010;29:50-5.
37. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-67. (Pubitemid 30029305)
38. Bean D, Cundy T, Petrie KJ. Ethnic differences in illness perceptions, self-efficacy and diabetes self-care. Psychol Health 2007;22:787-811.
39. Barnes L, Moss-Morris R, Kaufusi M. Illness beliefs and adherence in diabetes mellitus: a comparison between Tongan and European patients. N Z Med J 2004;117:U743. URL: http://www.nzma.org.nz/journal/117-1188/743/.
40. Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990; 17:1450-2.
41. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al, for The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992;10:549-54.
42. Harrison MJ, Morris KA, Horton R, Toglia J, Barsky J, Chait S, et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 2005;65: 1325-7. (Pubitemid 41508241)